knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 00:58:03 - browse：27393

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： A protest over insulin prices is seen as a fight for life

focus

WSS

Why Novartis is going to walk from its acquisition of MorphoSys

Surgery pushed Ben Carson to fame

Adopting new red light myopia treatments may be short

The Biogen Aduhelm mess could happen again

AI gets buy

The CDC's new social media misinformation war

Wikipedia

knowledge

knowledge

Supreme Court strikes down use of affirmative action

Johnson & Johnson sued for allegedly overpaying for workers' drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

The Biogen Aduhelm mess could happen again

Apple is now the first public company to be valued at $3 trillion

Problems with a popular proposal to regulate AI in health care

In age of alternative facts, a scholarly course on calling out crap

Global cancer cases to surge 77% by 2050, WHO report says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Devoted Health’s losses in Medicare Advantage persist

entertainment

AstraZeneca stays mum on Medicare drug pricing negotiations

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Texas Medical Board asked to define abortion emergency exception

Cano Health’s bankruptcy is a warning for Medicare Advantage

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Wikipedia

focus

focus

hotspot